Comparison
Berberine vs GHK-Cu
Side-by-side of Berberine and GHK-Cu. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Berberine
Berberine supplement guide: 1500 mg/day lowers fasting glucose and HbA1c, AMPK activation, metformin parity in RCTs, dihydroberberine absorption.
GHK-Cu
GHK-Cu peptide (glycyl-L-histidyl-L-lysine copper) is a topical copper peptide. Trials show fine-line and wound-healing gains; injectable longevity claims rem.
Effects at a glance
Berberine
- •Lowers HbA1c by ~0.7% versus placebo at 1500 mg/day across 27-trial meta-analysis (Lan 2015)
- •Roughly comparable to metformin on fasting glucose and HbA1c in small head-to-head RCTs (Yin 2008)
- •Reduces LDL cholesterol 10-20% and triglycerides 15-25% via PCSK9 inhibition
- •Activates AMPK, the cellular energy sensor that drives insulin-independent glucose uptake
- •Oral bioavailability under 1%; dihydroberberine is the higher-absorption alternative at lower doses
- •GI side effects affect 10-30% at 1500 mg/day; split dosing with meals reduces incidence
GHK-Cu
- •Endogenous tripeptide that binds copper(II); plasma levels decline ~60% from age 20 to 60
- •Topical RCTs show improvement in skin firmness, fine lines, and barrier function over 12 weeks
- •Wound-healing models report accelerated re-epithelialization in diabetic and aged skin
- •Pickart gene-expression analyses show reset of >4000 genes toward a younger expression profile in cell culture
- •Anecdotal subcutaneous longevity protocols use 1 to 3 mg daily; no human longevity RCTs exist
- •Hair-growth claims rest on small open-label trials and topical scalp formulations
Side-by-side
| Attribute | Berberine | GHK-Cu |
|---|---|---|
| Category | natural | peptide |
| Also known as | berberine HCl, berberine hydrochloride | Copper Peptide, Glycyl-L-histidyl-L-lysine copper, GHK |
| Half-life (hr) ↗ | 3 | 0.5 |
| Typical dose (mg) ↗ | 1500 | 2 |
| Dosing frequency | 3x daily with meals | daily |
| Routes | oral | topical, subcutaneous |
| Onset (hr) | 2 | 24 |
| Peak (hr) | 3 | 168 |
| Molecular weight | 336.36 | 340.85 |
| Molecular formula | C20H18NO4+ | C14H24N6O4 (GHK alone); C14H22CuN6O4 with Cu(II) |
| Mechanism | Activates AMP-activated protein kinase (AMPK), suppressing hepatic gluconeogenesis and lipogenesis while increasing peripheral glucose uptake. Inhibits PCSK9 transcription, modulates bile acid signaling, and shifts gut microbiome composition. | Tripeptide that chelates Cu(II) and delivers it to copper-dependent enzymes (lysyl oxidase, superoxide dismutase). Modulates expression of >4000 genes toward a younger profile in fibroblast culture, including upregulation of decorin and downregulation of pro-inflammatory cytokines. |
| Legal status | Dietary supplement (US, EU, UK, Canada); Rx in some Asian jurisdictions | Topical cosmetics legal in most jurisdictions; injectable form not FDA approved for any indication; research-use-only grey market |
| WADA status | allowed | allowed |
| DEA / Rx | Not scheduled | Topical OTC (cosmetic); injectable not FDA approved; research-chemical status |
| Pregnancy | Contraindicated (kernicterus risk in neonates) | Insufficient data; topical use likely low-risk; injectable not recommended |
| CAS | 2086-83-1 | 49557-75-7 |
| PubChem CID | 2353 | 73587 |
| Wikidata | Q411435 | Q3104638 |
Safety profile
Berberine
Common side effects
- constipation
- diarrhea
- abdominal cramping
- flatulence
- nausea
Contraindications
- pregnancy
- lactation
- neonatal jaundice
- severe liver disease
Interactions
- metformin: additive HbA1c reduction; additive GI side effects(moderate)
- insulin or sulfonylureas: additive hypoglycemia risk; dose adjustment may be required(major)
- statins (simvastatin, atorvastatin): CYP3A4 inhibition raises statin plasma levels(moderate)
- cyclosporine: raises cyclosporine levels through CYP3A4 and P-gp inhibition(major)
- calcium channel blockers (amlodipine): elevated plasma levels via CYP3A4 inhibition(moderate)
GHK-Cu
Common side effects
- mild erythema at topical site
- transient itch
- blue-green discoloration of injection site (copper)
- rare contact dermatitis
Contraindications
- copper allergy
- Wilson disease
- open wound near injection site (caution)
- pregnancy (no data)
Interactions
- topical retinoids: additive irritation; alternate days or apply at different times(minor)
- topical vitamin C (ascorbic acid): ascorbate reduces Cu(II) to Cu(I), which can destabilize the GHK-Cu complex; separate by 30 minutes(minor)
Which Should You Take?
Berberine comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. GHK-Cu is the right call when one of the conditionals below applies.
- → If your priority is metabolic health and glucose control, pick Berberine.
- → If your priority is cardiovascular health, pick Berberine.
- → If your priority is skin health, pick GHK-Cu.
- → If your priority is wound healing, pick GHK-Cu.
Edge case: If you want to avoid research-only / gray-market sourcing, Berberine is the more accessible choice.
Default choice: Berberine. Lower friction to source, and broader goal coverage. Reach for GHK-Cu only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Berberine and GHK-Cu?
Berberine and GHK-Cu differ in category (natural vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Berberine or GHK-Cu?
Berberine half-life is 3 hours; GHK-Cu half-life is 0.5 hours.
Can you stack Berberine with GHK-Cu?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper